5JD0 Stock Overview
Through its subsidiary, ExpreS2ion Biotechnologies ApS, researches and develops preventive and therapeutic vaccine products in the Nordics and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ExpreS2ion Biotech Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.12 |
| 52 Week High | SEK 12.36 |
| 52 Week Low | SEK 1.56 |
| Beta | 1.73 |
| 1 Month Change | 10.88% |
| 3 Month Change | -41.11% |
| 1 Year Change | -73.70% |
| 3 Year Change | -98.15% |
| 5 Year Change | n/a |
| Change since IPO | -97.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5JD0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 11.6% | 2.5% | -0.4% |
| 1Y | -73.7% | -10.2% | 7.9% |
Return vs Industry: 5JD0 underperformed the German Biotechs industry which returned -10.2% over the past year.
Return vs Market: 5JD0 underperformed the German Market which returned 7.9% over the past year.
Price Volatility
| 5JD0 volatility | |
|---|---|
| 5JD0 Average Weekly Movement | 29.4% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5JD0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5JD0's weekly volatility (29%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 18 | Bent Frandsen | www.expres2ionbio.com |
ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2ion Biotechnologies ApS, researches and develops preventive and therapeutic vaccine products in the Nordics and internationally. The company’s lead asset is ES2B-C001, a therapeutic vaccine for breast cancer that targets the human epidermal growth factor receptor 2 receptor. It is also developing ES2B-I002, a cytomegalovirus vaccine candidate to treat infectious diseases.
ExpreS2ion Biotech Holding AB (publ) Fundamentals Summary
| 5JD0 fundamental statistics | |
|---|---|
| Market cap | €4.59m |
| Earnings (TTM) | -€2.97m |
| Revenue (TTM) | €693.13k |
6.6x
P/S Ratio-1.5x
P/E RatioIs 5JD0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5JD0 income statement (TTM) | |
|---|---|
| Revenue | SEK 7.93m |
| Cost of Revenue | SEK 4.07m |
| Gross Profit | SEK 3.86m |
| Other Expenses | SEK 37.86m |
| Earnings | -SEK 34.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | -16.19 |
| Gross Margin | 48.66% |
| Net Profit Margin | -428.76% |
| Debt/Equity Ratio | 0.5% |
How did 5JD0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 13:24 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ExpreS2ion Biotech Holding AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dennis Berzhanin | Pareto Securities |